UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
July 22, 2014
AMARANTUS BIOSCIENCE HOLDINGS, INC.
(Exact name of registrant as specified in
its charter)
Nevada |
000-555016 |
26-0690857 |
(State or other jurisdiction of incorporation or organization) |
(Commission File Number) |
IRS Employer
Identification No.) |
c/o Janssen Labs @QB3
953 Indiana Street
San Francisco, CA |
94107 |
(Address of Principal Executive Offices) |
(Zip Code) |
(408) 737-2734
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Effective July 22,
2014, Don Huffman was appointed as a director and Chairman of the Audit Committee of the Board of Directors of Amarantus Bioscience
Holdings, Inc. (the “Company”).
Mr. Huffman, age 67, served as a consultant
to Dance BioPharma, Inc., a company developing inhaled insulin, from April 2012 to July 2013 and has served as a Director since
July 2013. From September 2010 to March 2012, Mr. Huffman served as the Chief Financial Officer of Wafergen Biosystems Inc., a
publicly-held emerging genomic analysis company and was its Co-President from September 2011 to March 2012. From October 2008 to
September 2010, Mr. Huffman served as the Chief Financial Officer of Asante Solutions, Inc., a medical device company with an approved
wearable insulin pump. From July 2006 to October 2008, Mr. Huffman served as Chief Financial Officer of Guava Technologies, Inc.,
a life science instrumentation company acquired by Millipore Corporation and then Merck & Co., Inc. From October 2004 to July
2006, Mr. Huffman served as Chief Financial Officer and principal of Sanderling Ventures, a biomedical venture capital firm. Mr.
Huffman also has served as the Chief Financial Officer of three other public companies: Volcano Corporation (formerly known as
EndoSonics Corporation), a company that manufactures medical devices; Microcide Pharmaceuticals, Inc., a biopharmaceutical company;
and Celtrix Pharmaceuticals, Inc., a company that developed novel therapeutics for the treatment of debilitating, degenerative
conditions, which was acquired by Insmed Incorporated in 2000. Mr. Huffman earned a B.S. in Mineral Economics from Pennsylvania
State University and an M.B.A. from the State University of New York at Buffalo. He completed the Financial Management Program
at the Stanford University Graduate School of Business.
We believe that Mr. Huffman possesses specific
attributes that qualify him to serve on our board of directors, including his experience as a Chief Financial Officer of several
public biopharmaceutical and medical device companies and his understanding of the operations and issues that affect similarly
situated companies. Based on Mr. Huffman’s extensive senior management experience in the biopharmaceutical and medical device
industries, particularly in previous key corporate finance and accounting positions as Chief Financial Officer of four public companies,
we have determined that he qualifies as an audit committee financial expert as defined in Item 407 of Regulation S-K.
Mr. Huffman has no family relationship with
any of the executive officers or directors of the Company. There are no arrangements or understandings between Mr. Huffman
and any other person pursuant to which he was appointed as a director of the Company.
A copy of the Company’s press release
announcing Mr. Huffman’s appointment is attached as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
99.1 Press Release dated July 28, 2014.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
|
|
|
AMARANTUS BIOSCIENCE HOLDINGS, INC. |
|
|
|
|
|
|
|
|
|
|
|
|
Date: July 28, 2014 |
|
By: |
/s/ Gerald E. Commissiong |
|
|
|
|
|
Name: Gerald E. Commissiong |
|
|
|
|
|
Title: Chief Executive Officer |
|
Exhibit 99.1
Amarantus Appoints Donald D. Huffman
to Board of Directors
Mr. Huffman to Chair Audit Committee
San Francisco, CA and Geneva, SWITZERLAND – July 28,
2014 - Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on the discovery and development
of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and
apoptosis, today announced the appointment of Donald D. Huffman to the Company’s Board of Directors, where he will chair
the newly-formed audit committee. Mr. Huffman brings over 20 years of biopharmaceutical industry experience in various financial
and audit roles, with specific expertise in mergers & acquisitions.
“I am extremely pleased to be joining Amarantus at this
juncture as the Company prepares for listing on a national exchange in the coming months,” said Mr. Huffman. “The Company
has made substantial strides recently, positioning itself for significant growth, and I will work closely with the team to further
these efforts. The set of assets assembled which span neurological, ophthalmological and metabolic indications is impressive, and
being woven into a cohesive story around biological pathways. This is the future of how science, biology and medicine will interplay
and I believe we are at the forefront. I am excited to begin my journey with Amarantus.”
Mr. Huffman currently serves as a Director of Dance Biopharm
Inc., a diabetes company entering Phase 3 clinical development with an inhaled insulin program. Previously, Mr. Huffman served
as the Chief Financial Officer of Wafergen Biosystems Inc., a publicly-held emerging genomic analysis company and was its Co-President
from September 2011 to March 2012. Before that, Mr. Huffman served as the Chief Financial Officer of Asante Solutions, Inc., a
medical device company with an approved wearable insulin pump. Mr. Huffman also served as Chief Financial Officer of Guava Technologies,
Inc., a life science instrumentation company acquired by Millipore Corporation and then Merck & Co., Inc. Previous to that
he served as Chief Financial Officer and principal of Sanderling Ventures, a biomedical venture capital firm. Mr. Huffman has also
served as the Chief Financial Officer of three other public companies: Volcano Corporation (formerly known as EndoSonics Corporation),
Microcide Pharmaceuticals, Inc., and Celtrix Pharmaceuticals, Inc., which was acquired by Insmed Incorporated in 2000. Mr. Huffman
earned a B.S. degree in Mineral Economics from Pennsylvania State University and an M.B.A. from the State University of New York
at Buffalo. He completed the Financial Management Program at the Stanford University Graduate School of Business.
“Don will bring tremendous experience, strategic thinking,
and an extensive network of relationships to Amarantus,” said Gerald E. Commissiong, President & CEO of Amarantus. “It
is clear that Don’s expertise in mergers & acquisitions, and spin-outs is robust, and will help us as we seek to maximize
long-term shareholder value from our current set of assets, and contemplate new asset opportunities and structures. We are extremely
pleased to welcome Don to the Amarantus team.”
About Amarantus BioScience Holdings, Inc.
Amarantus BioScience Holdings (AMBS) is a biotechnology company
developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis.
AMBS has licensed Eltoprazine ("Eltoprazine"), a phase 2b ready small molecule indicated for Parkinson's Levodopa induced
dyskinesia and Adult ADHD. AMBS has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test(R)")
for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived
Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. AMBS also owns
intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors
("PhenoGuard"). Amarantus operations are located at Janssen Labs @QB3 in San Francisco, CA. For further information please
visit www.Amarantus.com, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.
CONTACTS
Amarantus Bioscience Holdings, Inc.:
Aimee Boutcher, Investor Relations
408.737.2734 x 101
ir@amarantus.com
Certain statements, other than purely historical information,
including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the
assumptions upon which those statements are based, are forward-looking statements.” These forward-looking statements generally
are identified by the words believes,” project,” expects,” anticipates,” estimates,” intends,”
strategy,” plan,” may,” will,” would,” will be,” will continue,” will likely result,”
and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks
and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict
results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse
effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions,
legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles.
These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not
be placed on such statements.
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Sep 2023 to Sep 2024